Triumph Bancorp Announces Pricing of $50 million of Fixed-to-Floating Rate Subordinated Notes
Sep 29, 2016 00:26 am UTC| Business
DALLAS, Sept. 28, 2016 -- Triumph Bancorp, Inc. (NASDAQ:TBK) (“Triumph” or the “Company”) today announced the pricing of its public offering of $50 million aggregate principal amount of its Fixed-to-Floating Rate...
Mimecast Limited Announces Pricing of Secondary Offering
Sep 29, 2016 00:02 am UTC| Business
Watertown, MA, Sept. 28, 2016 -- Mimecast Limited (NASDAQ: MIME), a leading provider of next generation cloud security and risk management services for corporate information and email, today announced the pricing of a...
Alcobra Announces IND Clinical Hold Affecting the MDX Phase III MEASURE Study
Sep 29, 2016 00:01 am UTC| Business
TEL AVIV, Israel, Sept. 28, 2016 -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit...
Sep 28, 2016 23:39 pm UTC| Business
PLEASANTON, Calif., Sept. 28, 2016 -- Blackhawk Network Holdings, Inc. (Nasdaq:HAWK) will announce its third quarter 2016 earnings results on Tuesday, October 11, 2016. A press release will be sent out at approximately...
ISS Recommends Cynapsus Therapeutics Securityholders Vote for the Plan of Arrangement
Sep 28, 2016 23:27 pm UTC| Business
TORONTO, Sept. 28, 2016 -- Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX:CTH) is pleased to announce today that Institutional Shareholder Services (“ISS”), a leading independent proxy advisory firm, has...
Fulgent Genetics, Inc. Announces Pricing of Initial Public Offering
Sep 28, 2016 23:02 pm UTC| Business
TEMPLE CITY, Calif., Sept. 28, 2016 -- Fulgent Genetics announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $9.00 per share, before...
Apricus Biosciences Closes $3.7 Million Registered Direct Offering
Sep 28, 2016 23:00 pm UTC| Business
SAN DIEGO, Sept. 28, 2016 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has closed a registered direct...